Drug recall · November 5, 2025
HADLIMA recall
Why: Lack of Assurance of Sterility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.
- Lots / codes
Lot: F2505017, Expiry: 24-Jan-2027
- Quantity
- 5,518 packs (11,036 Syringes) 2 syringes/carton)
- Company
- Samsung Bioepis Co., Ltd., Yeonsu, N/A
- Distribution
- Distributed only to one warehouse in NJ. with no further distribution
- Initiated
- October 10, 2025 · Voluntary: Firm initiated
- Classified
- October 24, 2025
- Reported
- November 5, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hadlima
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.